Lynk 003 : A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

• NCT04456699
• MK-7339-003

Scientific Title

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Commercial Sponsor

Merck

Summary

Eligible patients will be randomised into one of three arms of the study. In the first arm, patients will receive oral Olaparib twice daily and intravenous Bevacizumab once every two weeks, until progressive disease or end of the study. In the second arm, patients will receive oral Olaparib alone, twice daily, until progressive disease or end of the study. In the third arm, the active comparator arm, patients will receive intravenous Bevacizumab every two weeks and 5-FU chemotherapy every two weeks, until progressive disease or end of study.